Cubist Systematic Strategies LLC purchased a new stake in shares of Agenus Inc (NASDAQ:AGEN) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 30,488 shares of the biotechnology company’s stock, valued at approximately $134,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AGEN. Artal Group S.A. grew its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after purchasing an additional 500,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Agenus by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after purchasing an additional 174,162 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Agenus by 511.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 88,942 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 74,407 shares in the last quarter. Candriam Luxembourg S.C.A. grew its position in shares of Agenus by 12.8% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock valued at $2,724,000 after purchasing an additional 70,000 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of Agenus during the 2nd quarter valued at $251,000. Hedge funds and other institutional investors own 37.87% of the company’s stock.

In related news, CEO Garo H. Armen bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was bought at an average cost of $3.55 per share, for a total transaction of $355,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Karen Valentine sold 8,358 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $3.46, for a total transaction of $28,918.68. Following the completion of the transaction, the insider now owns 109,879 shares of the company’s stock, valued at $380,181.34. The disclosure for this sale can be found here. Insiders sold 20,514 shares of company stock valued at $70,978 over the last quarter. 7.60% of the stock is owned by company insiders.

A number of research analysts have recently commented on AGEN shares. BidaskClub lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 3rd. ValuEngine lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Friday, December 29th. Finally, Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Wednesday, October 25th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Agenus presently has a consensus rating of “Hold” and an average target price of $5.88.

Agenus Inc (NASDAQ:AGEN) opened at $3.87 on Friday. The company has a market cap of $336.69, a price-to-earnings ratio of -3.31 and a beta of 2.11. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39. Agenus Inc has a 1 year low of $3.20 and a 1 year high of $5.45.

Agenus (NASDAQ:AGEN) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37). The company had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $5.91 million. The company’s revenue was down 24.4% compared to the same quarter last year. sell-side analysts anticipate that Agenus Inc will post -1.16 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Cubist Systematic Strategies LLC Invests $134,000 in Agenus Inc (AGEN)” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/cubist-systematic-strategies-llc-invests-134000-in-agenus-inc-agen/1806603.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.